Virtual Library

Start Your Search

X. Liao

Author of

  • +

    P1.01 - Advanced NSCLC (ID 757)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P1.01-048 - Clinical Impact of EGFR Mutation on Brain Metastasis in NSCLC Patients: A Meta-Regression Analysis (ID 7312)

      09:30 - 16:00  |  Author(s): X. Liao

      • Abstract
      • Slides

      Though target agents like epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have shown activity in patients with brain metastasis, the impact of EGFR mutation on incidence of non-small cell lung cancer (NSCLC) with brain metastasis and treatment outcome remain inconclusive.

      MEDLINE, PubMed, and EBSCO Libraries were systematically searched until August 31, 2015. Retrospective studies including investigating the correlation between EGFR mutation status with brain metastasis from NSCLC were included.

      The result of the fourteen studies including 4432 patients indicated NSCLC patients with EGFR mutation have higher incidence of brain metastasis (Figure 1, odd ratio = 2.09, 95% CI: 1.72–2.53). And, EGFR mutations were associated with better survival in patients with brain metastasis from five studies though not statistically significant (Figure 2, hazard ratio = 0.47, 95% CI: 0.16–1.35). Figure 1. Meta-analysis of the association between EGFR mutation status and the risk of brain metastasis. Figure 1 Figure 2. Meta-analysis on mean overall survival among NSCLC patients with brain metastasis according to EGFR mutation status. Figure 2

      We found that EGFR mutation increased risk of brain metastasis but EGFR mutation might predict better survival with appropriate treatments.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.